Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites - PubMed (original) (raw)
Removal of uremic retention products by hemodialysis is coupled with indiscriminate loss of vital metabolites
Zhi-Hao Zhang et al. Clin Biochem. 2017 Dec.
Abstract
Background: Although dialysis ameliorates uremia and fluid and electrolytes disorders, annual mortality rate remains high in dialysis population reflecting its shortcoming in replacing renal function. Unlike the normal kidney, dialysis causes dramatic shifts in volume and composition of body fluids and indiscriminate removal of vital solutes. Present study was undertaken to determine the impact of hemodialysis on plasma metabolites in end-stage renal disease (ESRD) patients.
Methods: 80 hemodialysis patients and 80 age/gender-matched healthy controls were enrolled in the study. Using ultra performance liquid chromatography-high-definition mass spectrometry, we measured plasma metabolites before, during, and after hemodialysis procedure and in blood entering and leaving the dialysis filter.
Results: Principal component analysis revealed significant difference in concentration of 214 metabolites between healthy control and ESRD patients' pre-dialysis plasma (126 increased and 88 reduced in ESRD group). Comparison of post-dialysis with pre-dialysis data revealed significant changes in the 362 metabolites. Among ESI+ metabolites 195 decreased and 55 increased and among ESI- metabolites 82 decreased and 30 increased following hemodialysis. Single blood passage through the dialyzer caused significant changes in 323 metabolites. Comparison of ESRD patients' post-hemodialysis with healthy subjects' data revealed marked differences in metabolic profiles. We identified 55 of the 362 differential metabolites including well known uremic toxins, waste products and vital biological compounds.
Conclusion: In addition to uremic toxins and waste products hemodialysis removes large number of identified and as-yet un-identified metabolites. Depletion of vital biological compounds by dialysis may contribute to the high morbidity and annual mortality rate in this population.
Keywords: Chronic kidney disease; Dialysis; End-stage renal disease; Metabolomics; Ultra performance liquid chromatography.
Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
Similar articles
- Optimized metabolomic approach to identify uremic solutes in plasma of stage 3-4 chronic kidney disease patients.
Mutsaers HA, Engelke UF, Wilmer MJ, Wetzels JF, Wevers RA, van den Heuvel LP, Hoenderop JG, Masereeuw R. Mutsaers HA, et al. PLoS One. 2013 Aug 2;8(8):e71199. doi: 10.1371/journal.pone.0071199. Print 2013. PLoS One. 2013. PMID: 23936492 Free PMC article. - Effects of end-stage renal disease and dialysis modalities on blood ammonia level.
Vaziri ND, Khazaeli M, Nunes ACF, Harley KT, Said H, Alipour O, Lau WL, Pahl MV. Vaziri ND, et al. Hemodial Int. 2017 Jul;21(3):343-347. doi: 10.1111/hdi.12510. Epub 2016 Nov 1. Hemodial Int. 2017. PMID: 27804262 Free PMC article. - Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease.
Jhawar S, Singh P, Torres D, Ramirez-Valle F, Kassem H, Banerjee T, Dolgalev I, Heguy A, Zavadil J, Lowenstein J. Jhawar S, et al. PLoS One. 2015 Mar 26;10(3):e0118703. doi: 10.1371/journal.pone.0118703. eCollection 2015. PLoS One. 2015. PMID: 25811877 Free PMC article. - Future Avenues to Decrease Uremic Toxin Concentration.
Vanholder RC, Eloot S, Glorieux GL. Vanholder RC, et al. Am J Kidney Dis. 2016 Apr;67(4):664-76. doi: 10.1053/j.ajkd.2015.08.029. Epub 2015 Oct 21. Am J Kidney Dis. 2016. PMID: 26500179 Review.
Cited by
- Network pharmacology and experimental validation to reveal the pharmacological mechanisms of Sini decoction against renal fibrosis.
Yan W, Fanying D, Shiqi L, Yingli W. Yan W, et al. J Tradit Chin Med. 2024 Apr;44(2):362-372. doi: 10.19852/j.cnki.jtcm.20230630.003. J Tradit Chin Med. 2024. PMID: 38504542 Free PMC article. - Mechanisms of norcantharidin against renal tubulointerstitial fibrosis.
Yun QS, Bao YX, Jiang JB, Guo Q. Yun QS, et al. Pharmacol Rep. 2024 Apr;76(2):263-272. doi: 10.1007/s43440-024-00578-5. Epub 2024 Mar 12. Pharmacol Rep. 2024. PMID: 38472637 Review. - Mechanisms Underlying the Differences in the Pharmacokinetics of Six Active Constituents of Huangqi Liuyi Decoction between Normal and Diabetic Nephropathy Mouse Models.
Wang Q, Wang Y, Liu W, Lu D, Jin Y, Tang N, Shi Y, Gong Z, Tian W, Liu T. Wang Q, et al. Evid Based Complement Alternat Med. 2022 Oct 15;2022:2481654. doi: 10.1155/2022/2481654. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 36285162 Free PMC article. - Autophagy in renal fibrosis: Protection or promotion?
Dai R, Zhang L, Jin H, Wang D, Cheng M, Sang T, Peng C, Li Y, Wang Y. Dai R, et al. Front Pharmacol. 2022 Aug 24;13:963920. doi: 10.3389/fphar.2022.963920. eCollection 2022. Front Pharmacol. 2022. PMID: 36105212 Free PMC article. Review. - Pharmacokinetic Difference of Six Active Constituents of Huangqi Liuyi Decoction between Control and Diabetic Nephropathy Mouse Models.
Wang Q, Shi Y, Liu X, Liu T, Li Y, Song X, Chen X, Jin Y, Liu W, Wang Y, Gong Z. Wang Q, et al. Int J Anal Chem. 2022 May 25;2022:7602992. doi: 10.1155/2022/7602992. eCollection 2022. Int J Anal Chem. 2022. PMID: 35663235 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical